Read by QxMD icon Read

Rheumatoid Arthritis

shared collection
267 papers 25 to 100 followers
George A Karpouzas, Joel Estis, Panteha Rezaeian, John Todd, Matthew J Budoff
Objectives: Patients with RA display greater occult coronary atherosclerosis burden and experience higher cardiovascular morbidity and mortality compared with controls. We here explored whether pro-inflammatory cytokines and high-sensitivity cardiac troponin I (hs-cTnI), a biomarker of myocardial injury, correlated with plaque burden and cardiovascular events (CVEs) in RA. Methods: We evaluated 150 patients with 64-slice coronary CT angiography. Coronary artery calcium, number of segments with plaque (segment involvement score), stenotic severity and plaque burden were assessed...
March 14, 2018: Rheumatology
Imran H Yusuf, Joanna M Ledingham, Elizabeth MacPhie, Andrew J Lotery, James Galloway
No abstract text is available yet for this article.
February 26, 2018: Rheumatology
Andrea Rubbert-Roth, Daniel E Furst, Jan Michael Nebesky, Angela Jin, Erhan Berber
Tocilizumab (TCZ) is the first humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody approved for the treatment of patients with rheumatoid arthritis (RA), Castleman's disease, polyarticular and systemic juvenile idiopathic arthritis, and, most recently, giant cell arteritis as well as for the treatment of chimeric antigen receptor T cell therapy-induced cytokine release syndrome. The global clinical development program for TCZ provides a wealth of clinical data on intravenous TCZ, and more recent studies in patients with RA have provided evidence characterizing the role of intravenous TCZ as monotherapy in early disease and led to the introduction of a subcutaneous formulation of TCZ...
March 3, 2018: Rheumatology and Therapy
Andrew I Rutherford, Eunice Patarata, Sujith Subesinghe, Kimme L Hyrich, James B Galloway
Objectives: This analysis set out to estimate the risk of opportunistic infection (OI) among patients with RA by biologic class. Methods: The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis is a prospective observational cohort study established to evaluate safety of biologic therapies. The population included adults commencing biologic therapy for RA. The primary outcome was any serious OI excluding tuberculosis (TB). Event rates were compared across biologic classes using Cox proportional hazards with adjustment for potential confounders identified a priori...
February 26, 2018: Rheumatology
Jon T Einarsson, Minna Willim, Sofia Ernestam, Tore Saxne, Pierre Geborek, Meliha C Kapetanovic
Objectives: The aims of this national study in Sweden of patients with RA were to: examine the prevalence of sustained remission (SR), that is, remission lasting for at least 6 months; compare the prevalence of SR in patients with early RA and established RA; study the timing of onset of and time spent in SR; and study possible predictors of SR. Methods: Adult patients with RA included in the Swedish Rheumatology Quality registry were studied. The registry was searched for patients fulfilling remission criteria: DAS28-ESR, Clinical Disease Activity Index (CDAI), Simplified Disease Activity Index (SDAI) and ACR/EULAR remission for at least 6 months...
March 12, 2018: Rheumatology
Adeline Ruyssen-Witrand, Arnaud Constantin
Despite therapeutic innovations in the past 20 years, glucocorticoids (GC) are still widely used for the symptomatic treatment of rheumatoid arthritis (RA). Studies have demonstrated the clinical and structural efficacy of moderate doses (i.e. 30-60 mg/d) GC in addition to disease modifying anti-rheumatic drug (DMARD) initiation in early RA. A combination of a low dose of GC (i.e. 7.5-10 mg/d) and DMARDs increases remission rates and decreases the risk of medium-term structural progression in early RA. Intravenous and intramuscular administration of GC associated with DMARD initiation or intra-articular GC injections in symptomatic joints in tight control strategies increase remission rates in early RA...
December 12, 2017: Joint, Bone, Spine: Revue du Rhumatisme
(no author information available yet)
No abstract text is available yet for this article.
February 28, 2018: Rheumatology
Dag Leonard, Elisabet Svenungsson, Johanna Dahlqvist, Andrei Alexsson, Lisbeth Ärlestig, Kimberly E Taylor, Johanna K Sandling, Christine Bengtsson, Martina Frodlund, Andreas Jönsen, Susanna Eketjäll, Kerstin Jensen-Urstad, Iva Gunnarsson, Christopher Sjöwall, Anders A Bengtsson, Maija-Leena Eloranta, Ann-Christine Syvänen, Solbritt Rantapää-Dahlqvist, Lindsey A Criswell, Lars Rönnblom
OBJECTIVES: Patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) have increased risk of cardiovascular disease (CVD). We investigated whether single nucleotide polymorphisms (SNPs) at autoimmunity risk loci were associated with CVD in SLE and RA. METHODS: Patients with SLE (n=1045) were genotyped using the 200K Immunochip SNP array (Illumina). The allele frequency was compared between patients with and without different manifestations of CVD...
March 7, 2018: Annals of the Rheumatic Diseases
Ruth Ann Marrie, Carol A Hitchon, Randy Walld, Scott B Patten, James M Bolton, Jitender Sareen, John R Walker, Alexander Singer, Lisa M Lix, Renée El-Gabalawy, Alan Katz, John D Fisk, Charles N Bernstein
OBJECTIVE: We estimated the incidence and prevalence of depression, anxiety disorder, bipolar disorder and schizophrenia in a population-based cohort with rheumatoid arthritis (RA) as compared to an age-, sex- and geographically matched cohort without RA. METHODS: Using population-based administrative health data from Manitoba, Canada, we identified persons with incident RA between 1989 and 2012, and a cohort from the general population matched 5:1 on year of birth, sex and region...
February 13, 2018: Arthritis Care & Research
Jessica Widdifield, J Michael Paterson, Anjie Huang, Sasha Bernatsky
OBJECTIVE: To compare mortality rates, underlying causes of death, excess mortality and years of potential life lost (YPLL) among rheumatoid arthritis (RA) patients relative to the general population. METHODS: We studied an inception cohort of 87,114 Ontario RA patients and 348,456 age/sex/area-matched general population comparators over 2000 to 2013. All-cause, cause-specific, and excess mortality rates, mortality rate ratios (MRRs), and YPLL were estimated. RESULTS: A total of 11,778 (14% of) RA patients and 32,472 (9% of) comparators died during 508,385 and 1,769,365 person-years (PY) of follow-up, respectively, for corresponding mortality rates of 232 (95% CI 228, 236) and 184 (95% CI 182, 186) per 10,000 PYs...
March 7, 2018: Arthritis Care & Research
Lydia Ntari, Maria Sakkou, Panagiotis Chouvardas, Iordanis Mourouzis, Alejandro Prados, Maria C Denis, Niki Karagianni, Constantinos Pantos, George Kollias
OBJECTIVES: Patients with rheumatoid arthritis and spondyloarthritisshow higher mortality rates, mainly caused by cardiac comorbidities. The TghuTNF (Tg197) arthritis model develops tumour necrosis factor (TNF)-driven and mesenchymalsynovial fibroblast (SF)-dependent polyarthritis. Here, we investigate whether this model develops, similarly to human patients, comorbid heart pathology and explore cellular and molecular mechanisms linking arthritis to cardiac comorbidities. METHODS: Histopathological analysis and echocardiographic evaluation of cardiac function were performed in the Tg197 model...
February 23, 2018: Annals of the Rheumatic Diseases
Debbie M Boeters, Wouter P Nieuwenhuis, Hanna W van Steenbergen, Monique Reijnierse, Robert B M Landewé, Annette H M van der Helm-van Mil
OBJECTIVES: MRI is recommended in the diagnostic process of rheumatoid arthritis (RA) to detect joint damage early. MRI-detected erosions are also present in symptom-free controls, especially at older age. It is unclear if RA-specific MRI-detected erosions can be distinguished from 'physiological' erosions in symptom-free individuals. This study compared MRI-detected erosions of patients with RA with healthy controls and with other arthritides. METHODS: 589 newly presenting patients with early arthritis (238 RA, 351 other arthritides) and 193 symptom-free controls underwent contrast-enhanced 1...
February 28, 2018: Annals of the Rheumatic Diseases
Carlos Fernández-Díaz, Javier Loricera, Santos Castañeda, Raquel López-Mejías, Clara Ojeda-García, Alejandro Olivé, Samantha Rodríguez-Muguruza, Patricia E Carreira, Trinidad Pérez-Sandoval, Miriam Retuerto, Evelin C Cervantes-Pérez, Bryan J Flores-Robles, Blanca Hernández-Cruz, Ana Urruticoechea, Olga Maíz-Alonso, Luis Arboleya, Gema Bonilla, Íñigo Hernández-Rodríguez, Desirée Palma, Concepción Delgado, Rosa Expósito-Molinero, Ana Ruibal-Escribano, Belén Álvarez-Rodríguez, Juan Blanco-Madrigal, José A Bernal, Paloma Vela-Casasempere, Manuel Rodríguez-Gómez, Concepción Fito, Francisco Ortiz-Sanjuán, Javier Narváez, Manuel Moreno, Mireia López-Corbeto, Natalia Mena-Vázquez, Clara Aguilera-Cros, Susana Romero-Yuste, Sergi Ordóñez, Ignacio Villa-Blanco, M Carmen Gonzélez-Vela, Víctor Mora-Cuesta, Natalia Palmou-Fontana, José L Hernández, Miguel A González-Gay, Ricardo Blanco
OBJECTIVE: Interstitial lung disease (ILD) is one of the most serious complications of rheumatoid arthritis (RA). In the present study, we aimed to assess the efficacy of abatacept (ABA) in patients with ILD associated to RA. METHODS: National multicenter, non-controlled, open-label registry study of RA patients with ILD treated with ABA. RESULTS: 63 patients (36 women) with RA-associated ILD undergoing ABA therapy were studied. The mean ± standard deviation age at the time of the study was 63...
January 6, 2018: Seminars in Arthritis and Rheumatism
Amanda M Eudy, Anna Maria Siega-Riz, Stephanie M Engel, Nora Franceschini, Annie Green Howard, Megan E B Clowse, Michelle Petri
OBJECTIVE: Prior studies found conflicting results about whether lupus is likely to flare during or after pregnancy. Using a large cohort of pregnant and non-pregnant women with lupus, we estimated the effect of pregnancy on disease flares in systemic lupus erythematosus. METHODS: Data were collected in the Hopkins Lupus Cohort 1987-2015. Women aged 14-45 years with >1 measurement of disease activity were included. The time-varying exposures were classified as pregnancy, postpartum or non-pregnant/non-postpartum periods...
February 20, 2018: Annals of the Rheumatic Diseases
Peter C Taylor, Joel M Kremer, Paul Emery, Steven H Zuckerman, Giacomo Ruotolo, Jinglin Zhong, Lei Chen, Sarah Witt, Chadi Saifan, Monika Kurzawa, James D Otvos, Margery A Connelly, William L Macias, Douglas E Schlichting, Terence P Rooney, Stephanie de Bono, Iain B McInnes
OBJECTIVES: Lipid profiles are altered by active disease in patients with rheumatoid arthritis (RA) and may be further modified by treatment with Janus kinase inhibitors and other disease-modifying antirheumatic drugs. METHODS: Lipid data were analysed from phase II and III studies of 4 mg (n=997) and 2 mg (n=479) oral baricitinib administered once daily in patients with moderate-to-severe active RA. Lipoprotein particle size and number and GlycA were evaluated with nuclear magnetic resonance in one phase III study...
February 20, 2018: Annals of the Rheumatic Diseases
Francesco Ursini, Emilio Russo, Piero Ruscitti, Roberto Giacomelli, Giovambattista De Sarro
Inflammatory arthritides are chronic diseases characterised by an increase in cardiovascular risk, largely attributable to the synergy between high-grade systemic inflammation and an elevated prevalence of traditional cardiovascular risk factors. Amongst the latter, insulin resistance and type 2 diabetes (T2D) play a key position. Previous studies demonstrated a potential insulin-sensiting effect of anti-TNF biologic medications. For converse, less is known about the role of newer biologics or small molecules...
February 13, 2018: Autoimmunity Reviews
Hiroki Tawaratsumida, Takao Setoguchi, Yoshiya Arishima, Hideo Ohtsubo, Masaki Akimoto, Yasuhiro Ishidou, Satoshi Nagano, Eiji Taketomi, Nobuhiko Sunahara, Setsuro Komiya
OBJECTIVE: Osteoporosis is a complication of rheumatoid arthritis. We examined the risk factors for bone loss in rheumatoid arthritis patients receiving biological disease-modifying anti-rheumatic drugs. Lumbar spine and femoral neck bone mineral density was measured at two time points in 153 patients with rheumatoid arthritis managed with biological disease-modifying anti-rheumatic drugs. We examined patients' variables to identify risk factors for least significant reduction of bone mineral density...
December 21, 2017: BMC Research Notes
Line R Jølving, Jan Nielsen, Ulrik S Kesmodel, Rasmus G Nielsen, Signe S Beck-Nielsen, Bente M Nørgård
OBJECTIVE: Fetal exposure to maternal rheumatoid arthritis (RA) might impact the long-term risk of disease in the offspring. We examined a possible association between maternal RA and 15 selected groups of chronic diseases in the offspring. METHODS: This nationwide cohort study was based on the Danish health registries and included data on all children born alive in Denmark from January 1st 1989 to December 31st 2013. The cohort comprised 2106 children born by women with RA (exposed), and 1 378 539 children born by women without RA (unexposed)...
December 11, 2017: Arthritis Care & Research
Jeffrey R Curtis, Shuo Yang, Jasvinder A Singh, Fenglong Xie, Lang Chen, Huifeng Yun, Paul Muntner, Shia T Kent, Emily B Levitan, Monika M Safford, Kenneth G Saag, Jie Zhang
BACKGROUND/PURPOSE: The 2013 American College of Cardiology/American Heart Association (ACC/AHA) cholesterol treatment guidelines recommend statins for patients with diabetes aged 40-75 years due to their elevated cardiovascular disease (CVD) risk. We compared the incidence of hospitalized acute myocardial infarction (MI), stroke, and coronary revascularization according to whether patients had diabetes, rheumatoid arthritis (RA), both or neither. METHODS: Using 2006 to 2010 private and public health plan claims, we identified 4 mutually exclusive retrospective cohorts age>40: patients with 1) RA and diabetes; 2) RA only; 3) diabetes only; 4) neither condition...
February 6, 2018: Arthritis Care & Research
Guo-Min Li, Jie Zhao, Bing Li, Xiao-Fei Zhang, Jian-Xiong Ma, Xin-Long Ma, Jun Liu
BACKGROUND: Over the past several years, numerous studies investigated the anti-inflammatory effects of statin on patients with RA. However, the findings of the individual studies were often inconsistent or conflicting. MATERIALS AND METHODS: The Pubmed, Web of Science, Embase, Cochrane Library and CNKI literature databases were searched in order to identify randomized controlled clinical trials where the association between the anti-inflammatory effect of statin and RA was investigated...
January 17, 2018: Autoimmunity Reviews
2018-02-14 20:09:01
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"